4.2 Article

Metformin Can Enhance the Inhibitory Effect of Olaparib in Bladder Cancer Cells

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Review Urology & Nephrology

Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis

Zhenjie Wu et al.

Summary: This study comprehensively investigated the incidence and profile of adverse events associated with immune checkpoint inhibitor therapy in urologic cancer patients. The findings revealed variations in the spectrum and incidence of adverse events across different cancer types, immune checkpoint inhibitor types, clinical settings, and therapy combinations.

EUROPEAN UROLOGY (2022)

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Review Biochemistry & Molecular Biology

Multifaceted Mechanisms of Action of Metformin Which Have Been Unraveled One after Another in the Long History

Hideaki Kaneto et al.

Summary: Metformin, an insulin sensitizer, acts through various mechanisms to regulate blood glucose levels, including activating AMPK to inhibit fatty acid synthesis and gluconeogenesis, increasing glucose uptake, suppressing glucagon signaling, and reducing autophagy failure.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Article Biotechnology & Applied Microbiology

Targeting c-MET to Enhance the Efficacy of Olaparib in Prostate Cancer

Zhenwei Wang et al.

Summary: The combined use of the c-MET inhibitor PHA665752 and the PARP inhibitor olaparib effectively and synergistically blocks the growth of prostate cancer cell lines, reduces invasion and migration, and impairs the DNA damage response.

ONCOTARGETS AND THERAPY (2021)

Article Medicine, General & Internal

Olaparib for Metastatic Castration-Resistant Prostate Cancer

J. de Bono et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Biochemistry & Molecular Biology

Targeting Hypoxia Sensitizes TNBC to Cisplatin and Promotes Inhibition of Both Bulk and Cancer Stem Cells

Andrew Sulaiman et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Review Biochemistry & Molecular Biology

Current Status and Application of Metformin for Prostate Cancer: A Comprehensive Review

Hyun Kyu Ahn et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Review Oncology

Metformin and Breast Cancer: Molecular Targets

J. Faria et al.

JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2019)

Review Endocrinology & Metabolism

Metformin in cancer

Ritwika Mallik et al.

DIABETES RESEARCH AND CLINICAL PRACTICE (2018)

Editorial Material Pharmacology & Pharmacy

Comparison of the diabetes guidelines from the ADA/EASD and the AACE/ACE

Susan Cornell

JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION (2017)

Review Endocrinology & Metabolism

Diabetes and Cancer: a Review of Current Knowledge

J. Wojciechowska et al.

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2016)

Article Biochemistry & Molecular Biology

Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors

Yi Du et al.

NATURE MEDICINE (2016)

Review Geriatrics & Gerontology

PARP inhibitors: A new era of targeted therapy

Shifalika Tangutoori et al.

MATURITAS (2015)